Merck has ceased a study of the drug verubecestat for the treatment of people with mild to moderate Alzheimer’s disease after an external monitoring panel found “virtually no chance of finding a positive clinical effect," the company announced recently.
The panel, however, did recommend continuing to evaluate the same
drug in a separate study of patients with prodromal Alzheimer’s,
after noting that safety indicators “are not sufficient to warrant
stopping" such studies.
Results from the prodomal study are expected this month, while results from study that was cut short will be analyzed and presented
at an upcoming scientific meeting.
“Alzheimer’s disease is one of the most pressing and daunting
medical issues of our time, with inherent, substantial challenges to
developing an effective disease-modifying therapy for people with
mild-to-moderate disease,” Roger Perlmutter, president of Merck
Research Laboratories, said.
Merck cuts short Alzheimer's medication study
Organizations in this Story
Want to get notified whenever we write about Merck ?
Next time we write about Merck, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.Sign-up for Alerts